{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T04:32:50Z","timestamp":1783053170245,"version":"3.54.6"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"BioCartis"},{"DOI":"10.13039\/100001010","name":"James Graham Brown Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s40291-021-00528-4","type":"journal-article","created":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T10:08:49Z","timestamp":1620641329000},"page":"361-371","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Longitudinal Relationship between Idylla Plasma ctBRAF V600 Mutation Detection and Tumor Burden in Patients with Metastatic Melanoma"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2257-0579","authenticated-orcid":false,"given":"Mark William","family":"Linder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Egger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Van Meter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shesh N.","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Roland","family":"Valdes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa Barousse","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norah","family":"Alghamdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Chesney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,10]]},"reference":[{"key":"528_CR1","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.canlet.2017.06.030","volume":"404","author":"L Calapre","year":"2017","unstructured":"Calapre L, et al. Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma. Cancer Lett. 2017;404:62\u20139.","journal-title":"Cancer Lett"},{"issue":"28","key":"528_CR2","doi-asserted-by":"publisher","first-page":"e16328","DOI":"10.1097\/MD.0000000000016328","volume":"98","author":"CL Cowey","year":"2019","unstructured":"Cowey CL, et al. Real-world treatment patterns and clinical outcomes among patients with advanced melanoma: A retrospective, community oncology-based cohort study (A STROBE-compliant article). Medicine (Baltimore). 2019;98(28):e16328.","journal-title":"Medicine (Baltimore)"},{"issue":"25","key":"528_CR3","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.2217\/fon-2018-0964","volume":"15","author":"JJ Luke","year":"2019","unstructured":"Luke JJ, et al. Targeted agents or immuno-oncology therapies as first-line therapy for BRAF-mutated metastatic melanoma: a real-world study. Future Oncol. 2019;15(25):2933\u201342.","journal-title":"Future Oncol."},{"issue":"1","key":"528_CR4","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1158\/2159-8290.CD-13-0617","volume":"4","author":"EM Van Allen","year":"2014","unstructured":"Van Allen EM, et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov. 2014;4(1):94\u2013109.","journal-title":"Cancer Discov"},{"key":"528_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ejca.2017.05.033","volume":"82","author":"D Schadendorf","year":"2017","unstructured":"Schadendorf D, et al. Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. Eur J Cancer. 2017;82:45\u201355.","journal-title":"Eur J Cancer"},{"issue":"8","key":"528_CR6","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","volume":"14","author":"JJ Luke","year":"2017","unstructured":"Luke JJ, et al. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol. 2017;14(8):463\u201382.","journal-title":"Nat Rev Clin Oncol"},{"issue":"13","key":"528_CR7","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1200\/JCO.2015.64.0391","volume":"34","author":"FS Hodi","year":"2016","unstructured":"Hodi FS, et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J ClinOncol. 2016;34(13):1510\u20137.","journal-title":"J ClinOncol"},{"issue":"4","key":"528_CR8","first-page":"939","volume":"24","author":"AY Lee","year":"2017","unstructured":"Lee AY, et al. Patterns and timing of initial relapse in pathologic stage Ii melanoma patients. Ann SurgOncol. 2017;24(4):939\u201346.","journal-title":"Ann SurgOncol"},{"issue":"18","key":"528_CR9","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1200\/JCO.2009.26.2063","volume":"28","author":"E Romano","year":"2010","unstructured":"Romano E, et al. Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. J Clin Oncol. 2010;28(18):3042\u20137.","journal-title":"J Clin Oncol"},{"issue":"4","key":"528_CR10","first-page":"947","volume":"24","author":"TS Park","year":"2017","unstructured":"Park TS, et al. Routine computer tomography imaging for the detection of recurrences in high-risk melanoma patients. Ann SurgOncol. 2017;24(4):947\u201351.","journal-title":"Ann SurgOncol"},{"issue":"39","key":"528_CR11","doi-asserted-by":"publisher","first-page":"42008","DOI":"10.18632\/oncotarget.5788","volume":"6","author":"ES Gray","year":"2015","unstructured":"Gray ES, et al. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget. 2015;6(39):42008\u201318.","journal-title":"Oncotarget"},{"issue":"2","key":"528_CR12","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/jso.25324","volume":"119","author":"B Deschner","year":"2019","unstructured":"Deschner B, Wayne JD. Follow-up of the melanoma patient. J Surg Oncol. 2019;119(2):262\u20138.","journal-title":"J Surg Oncol"},{"issue":"3","key":"528_CR13","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1158\/1078-0432.CCR-15-0321","volume":"22","author":"A Santiago-Walker","year":"2016","unstructured":"Santiago-Walker A, et al. Correlation of BRAF mutation status in circulating-free DNA and tumor and association with clinical outcome across four BRAFi and MEKi clinical trials. Clin Cancer Res. 2016;22(3):567\u201374.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"528_CR14","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jaad.2016.02.1229","volume":"75","author":"S Podlipnik","year":"2016","unstructured":"Podlipnik S, et al. Performance of diagnostic tests in an intensive follow-up protocol for patients with American Joint Committee on Cancer (AJCC) stage IIB, IIC, and III localized primary melanoma: a prospective cohort study. J Am Acad Dermatol. 2016;75(3):516\u201324.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"528_CR15","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1200\/JCO.2003.01.091","volume":"21","author":"C Garbe","year":"2003","unstructured":"Garbe C, et al. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. J Clin Oncol. 2003;21(3):520\u20139.","journal-title":"J Clin Oncol"},{"issue":"1","key":"528_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.suronc.2014.01.002","volume":"23","author":"AM Rodriguez Rivera","year":"2014","unstructured":"Rodriguez Rivera AM, et al. Value of positron emission tomography scan in stage III cutaneous melanoma: a systematic review and meta-analysis. Surg Oncol. 2014;23(1):11\u20136.","journal-title":"Surg Oncol"},{"issue":"5","key":"528_CR17","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1111\/bjd.16833","volume":"180","author":"S Podlipnik","year":"2019","unstructured":"Podlipnik S, et al. Cost-effectiveness analysis of imaging strategy for an intensive follow-up of patients with American Joint Committee on Cancer stage IIB, IIC and III malignant melanoma. Br J Dermatol. 2019;180(5):1190\u20137.","journal-title":"Br J Dermatol"},{"issue":"6","key":"528_CR18","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1097\/SLA.0000000000000233","volume":"259","author":"NM Rueth","year":"2014","unstructured":"Rueth NM, et al. Is surveillance imaging effective for detecting surgically treatable recurrences in patients with melanoma? A comparative analysis of stage-specific surveillance strategies. Ann Surg. 2014;259(6):1215\u201322.","journal-title":"Ann Surg"},{"issue":"9","key":"528_CR19","first-page":"2762","volume":"23","author":"S Damude","year":"2016","unstructured":"Damude S, et al. The MELFO-study: prospective, randomized, clinical trial for the evaluation of a stage-adjusted reduced follow-up schedule in cutaneous melanoma patients-results after 1 year. Ann SurgOncol. 2016;23(9):2762\u201371.","journal-title":"Ann SurgOncol"},{"issue":"5","key":"528_CR20","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1001\/jamaoncol.2017.5332","volume":"4","author":"JH Lee","year":"2018","unstructured":"Lee JH, et al. Association between circulating tumor DNA and pseudoprogression in patients with metastatic melanoma treated with anti-programmed cell death 1 antibodiescirculating tumor DNA and Anti\u2013PD-1 pseudoprogression in melanomacirculating tumor DNA and anti\u2013PD-1 pseudoprogression in melanoma. JAMA Oncol. 2018;4(5):717\u201321.","journal-title":"JAMA Oncol"},{"issue":"5","key":"528_CR21","doi-asserted-by":"publisher","first-page":"357","DOI":"10.2217\/pgs-2018-0174","volume":"20","author":"P Muluhngwi","year":"2019","unstructured":"Muluhngwi P, et al. Cell-free DNA diagnostics: current and emerging applications in oncology. Pharmacogenomics. 2019;20(5):357\u201380.","journal-title":"Pharmacogenomics"},{"issue":"5","key":"528_CR22","first-page":"429","volume":"20","author":"NL Strotman Lindsay","year":"2016","unstructured":"Strotman Lindsay NL. Liquid biopsies in oncology and the current regulatory landscape. MolDiagn Therapy. 2016;20(5):429\u201336.","journal-title":"MolDiagn Therapy"},{"issue":"5","key":"528_CR23","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1158\/2159-8290.CD-15-1483","volume":"6","author":"C Alix-Panabieres","year":"2016","unstructured":"Alix-Panabieres C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov. 2016;6(5):479\u201391.","journal-title":"Cancer Discov"},{"issue":"224","key":"528_CR24","first-page":"224ra24","volume":"6","author":"C Bettegowda","year":"2014","unstructured":"Bettegowda C, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. SciTransl Med. 2014;6(224):224ra24.","journal-title":"SciTransl Med"},{"issue":"4","key":"528_CR25","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nrc.2017.7","volume":"17","author":"JCM Wan","year":"2017","unstructured":"Wan JCM, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17(4):223\u201338.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"528_CR26","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/CMR.0000000000000421","volume":"28","author":"C Bisschop","year":"2018","unstructured":"Bisschop C, et al. Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, Droplet Digital PCR, and the idylla mutation platform. Melanoma Res. 2018;28(2):96\u2013104.","journal-title":"Melanoma Res"},{"issue":"1","key":"528_CR27","first-page":"297","volume":"61","author":"MF Sanmamed","year":"2015","unstructured":"Sanmamed MF, et al. Quantitative Cell-free circulating <em>BRAF<\/em><sup>V600E<\/sup> mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors. ClinChem. 2015;61(1):297.","journal-title":"ClinChem"},{"issue":"3","key":"528_CR28","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/1878-0261.12037","volume":"11","author":"LF van Dessel","year":"2017","unstructured":"van Dessel LF, et al. Application of circulating tumor DNA in prospective clinical oncology trials\u2014standardization of preanalytical conditions. Mol Oncol. 2017;11(3):295\u2013304.","journal-title":"Mol Oncol"},{"issue":"90","key":"528_CR29","doi-asserted-by":"publisher","first-page":"36238","DOI":"10.18632\/oncotarget.26343","volume":"9","author":"E Long-Mira","year":"2018","unstructured":"Long-Mira E, et al. Monitoring BRAF and NRAS mutations with cell-free circulating tumor DNA from metastatic melanoma patients. Oncotarget. 2018;9(90):36238\u201349.","journal-title":"Oncotarget"},{"issue":"2","key":"528_CR30","doi-asserted-by":"publisher","first-page":"a003830","DOI":"10.1101\/mcs.a003830","volume":"5","author":"MR Al-Turkmani","year":"2019","unstructured":"Al-Turkmani MR, et al. Pancreatic cyst fluid harboring a KRAS mutation. Cold Spring HarbMol Case Stud. 2019;5(2):a003830.","journal-title":"Cold Spring HarbMol Case Stud"},{"issue":"3","key":"528_CR31","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3390\/diagnostics10030153","volume":"10","author":"GB Barra","year":"2020","unstructured":"Barra GB, et al. Serum has higher proportion of janus kinase 2 V617F mutation compared to paired EDTA-whole blood sample: a model for somatic mutation quantification usingqPCR and the 2(-\u2206\u2206Cq) Method. Diagnostics (Basel). 2020;10(3):153.","journal-title":"Diagnostics (Basel)"},{"issue":"2","key":"528_CR32","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"1","key":"528_CR33","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s12967-019-2051-8","volume":"17","author":"T Seremet","year":"2019","unstructured":"Seremet T, et al. Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy. J Transl Med. 2019;17(1):303.","journal-title":"J Transl Med"},{"issue":"2","key":"528_CR34","doi-asserted-by":"publisher","first-page":"113","DOI":"10.18632\/oncotarget.26451","volume":"10","author":"AC McEvoy","year":"2019","unstructured":"McEvoy AC, et al. Monitoring melanoma recurrence with circulating tumor DNA: a proof of concept from three case studies. Oncotarget. 2019;10(2):113\u201322.","journal-title":"Oncotarget"},{"issue":"29","key":"528_CR35","doi-asserted-by":"publisher","first-page":"26886","DOI":"10.18632\/oncotarget.4723","volume":"6","author":"F Janku","year":"2015","unstructured":"Janku F, et al. BRAF mutation testing with a rapid, fully integrated molecular diagnostics system. Oncotarget. 2015;6(29):26886.","journal-title":"Oncotarget"},{"issue":"6","key":"528_CR36","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1158\/1535-7163.MCT-15-0712","volume":"15","author":"F Janku","year":"2016","unstructured":"Janku F, et al. BRAF mutation testing in cell-free DNA from the plasma of patients with advanced cancers using a rapid, automated molecular diagnostics system. Mol Cancer Ther. 2016;15(6):1397\u2013404.","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"528_CR37","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1002\/1878-0261.12373","volume":"12","author":"SP Rowe","year":"2018","unstructured":"Rowe SP, et al. From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real-world setting. Mol Oncol. 2018;12(10):1661\u201372.","journal-title":"Mol Oncol"},{"issue":"1","key":"528_CR38","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.molonc.2015.09.005","volume":"10","author":"GA Chang","year":"2016","unstructured":"Chang GA, et al. Sensitivity of plasma BRAFmutant and NRASmutant cell-free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non-RECIST disease progression. Mol Oncol. 2016;10(1):157\u201365.","journal-title":"Mol Oncol"},{"issue":"5","key":"528_CR39","first-page":"830","volume":"64","author":"V Haselmann","year":"2018","unstructured":"Haselmann V, et al. Liquid profiling of circulating tumor DNA in plasma of melanoma patients for companion diagnostics and monitoring of BRAF inhibitor therapy. ClinChem. 2018;64(5):830.","journal-title":"ClinChem"},{"issue":"20","key":"528_CR40","doi-asserted-by":"publisher","first-page":"4960","DOI":"10.1158\/1078-0432.CCR-17-2386","volume":"24","author":"RW Joseph","year":"2018","unstructured":"Joseph RW, et al. Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab. Clin Cancer Res. 2018;24(20):4960\u20137.","journal-title":"Clin Cancer Res"}],"container-title":["Molecular Diagnosis &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-021-00528-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40291-021-00528-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-021-00528-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T08:17:34Z","timestamp":1621585054000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40291-021-00528-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["528"],"URL":"https:\/\/doi.org\/10.1007\/s40291-021-00528-4","relation":{},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"15 April 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors gratefully acknowledge support from BioCartis under the terms of a collaborative research agreement that provided instrumentation and reagents. Funding was also provided through the James Graham Brown Cancer Center. SN Rai was partly supported with Wendell Cherry Chair in Clinical Trial Research Fund, multiple National Institutes of Health (NIH) grants (5P20GM113226, PI: McClain; 1P42ES023716, PI: Srivastava; 5P30GM127607-02, PI: Jones; 1P20GM125504-01, PI: Lamont; 2U54HL120163, PI: Bhatnagar\/Robertson; 1P20GM135004, PI: Yan; 1R35ES0238373-01, PI: Cave; 1R01ES029846, PI: Bhatnagar; 1R01ES027778-01A1, PI: States; 1P30ES030283, PI: Sates), and Kentucky Council on Postsecondary Education grant (PON2 415 1900002934, PI: Chesney).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Mark W. Linder, Michael E. Egger, Tracy Van Meter, Shesh N. Rai, Roland Valdes Jr., Melissa Barousse Hall, Xiaoyong Wu, Norah Alghamdi, and Jason A. Chesney have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Plasma samples were collected by the James Graham Brown Cancer Center Multi-Disciplinary Melanoma Clinic biorepository at the University of Louisville under an ongoing IRB-approved protocol (IRB# 08.0388). This study was determined to be exempt from IRB review (reference number # 673708).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All subjects enrolled were consented under the approved IRB protocol, University of Louisville IRB# 08.0388.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Informed consent documentation included consent for publication of de-identified research data.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data that support the findings of this study are available on request from the corresponding author.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"ML: conceptualization, data curation, formal analysis, funding acquisition, investigation, methodology, project administration, writing original draft. ME: data analysis, writing original draft. TV: formal analysis, writing original draft. SR: data analysis, writing original draft. RV: writing original draft. MH: data curation, writing original draft. XW: data analysis. NA: methodology. JC: conceptualization, formal analysis, resources.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}